Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, reports that Rik J Deitsch, Chief Executive Officer, was interviewed by WallSt.net. The interview has been published on the WallSt.Net website, http://www.wallst.net/audio/audio.asp?symbol=NPHC&id=2299.
In the interview, Mr. Deitsch discusses Nutra Pharma's focus as an incubator of undervalued biotechnology holdings. He also focuses on the drug discovery research in diseases that lack therapeutic options, specifically HIV/AIDS, AMN, and Multiple Sclerosis (MS). Additionally, he discusses the Company's revenue producing medical devices division, which sells diagnostic test kits globally for the rapid identification of Tuberculosis and NonTuberculosis Mycobacterium.
WallSt.net is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The WallSt.Net interview with Rik J. Deitsch should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.